Ultimately, specific TRPM7 inhibitors such as Waixenicin A [48], could potentially be used to induce neuroblastoma differentiation, and may prove useful in treatment of neuroblastoma in future (pre-) clinical studies. This evidence concerns the gene TRPM7 and neuroblastoma.